No Cover Image

Journal article 997 views 123 downloads

The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes

Win L. Yin, Steve Bain Orcid Logo, Thinzar Min

Diabetes Therapy, Volume: 11, Issue: 4, Pages: 835 - 844

Swansea University Authors: Steve Bain Orcid Logo, Thinzar Min

  • 53944VOR.pdf

    PDF | Version of Record

    Released under the terms of a Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC).

    Download (293.61KB)

Check full text

DOI (Published version): 10.1007/s13300-020-00798-x

Abstract

This review examines the available literature on the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in type 2 diabetes mellitus. Diabetes is an important cause of end-stage renal disease requiring renal replacement therapy, and diabetic kidney disease is an independ...

Full description

Published in: Diabetes Therapy
ISSN: 1869-6953 1869-6961
Published: Springer Science and Business Media LLC 2020
Online Access: Check full text

URI: https://cronfa.swan.ac.uk/Record/cronfa53944
first_indexed 2020-04-15T03:47:42Z
last_indexed 2023-01-11T14:31:45Z
id cronfa53944
recordtype SURis
fullrecord <?xml version="1.0"?><rfc1807><datestamp>2022-12-02T18:49:20.9521425</datestamp><bib-version>v2</bib-version><id>53944</id><entry>2020-04-14</entry><title>The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes</title><swanseaauthors><author><sid>5399f4c6e6a70f3608a084ddb938511a</sid><ORCID>0000-0001-8519-4964</ORCID><firstname>Steve</firstname><surname>Bain</surname><name>Steve Bain</name><active>true</active><ethesisStudent>false</ethesisStudent></author><author><sid>27cba511a4800fefddb6885ffffdb8b2</sid><firstname>Thinzar</firstname><surname>Min</surname><name>Thinzar Min</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2020-04-14</date><deptcode>MEDS</deptcode><abstract>This review examines the available literature on the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in type 2 diabetes mellitus. Diabetes is an important cause of end-stage renal disease requiring renal replacement therapy, and diabetic kidney disease is an independent risk factor for cardiovascular disease (CVD). GLP-1RAs are proven to be safe in terms of CVD, and some of them have been shown to have a beneficial effect on cardiovascular outcomes. The effect of GLP-1RAs on hard renal endpoints has yet to be established; to date, there have been no published GLP-1RA clinical trials with primary renal endpoints. In this review, we discuss the evidence for a renal protective role of GLP-1RAs, highlighting the secondary renal outcomes from recent cardiovascular outcome trials of this class of glucose-lowering therapies.</abstract><type>Journal Article</type><journal>Diabetes Therapy</journal><volume>11</volume><journalNumber>4</journalNumber><paginationStart>835</paginationStart><paginationEnd>844</paginationEnd><publisher>Springer Science and Business Media LLC</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1869-6953</issnPrint><issnElectronic>1869-6961</issnElectronic><keywords>Chronic kidney disease; Diabetesrelated nephropathy; Diabetic nephropathy; Dipeptidyl peptidase-4 (DPP-4) inhibitors; Glucagon-like peptide-1 receptor agonists; Type 2 diabetes</keywords><publishedDay>1</publishedDay><publishedMonth>4</publishedMonth><publishedYear>2020</publishedYear><publishedDate>2020-04-01</publishedDate><doi>10.1007/s13300-020-00798-x</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm/><funders/><projectreference/><lastEdited>2022-12-02T18:49:20.9521425</lastEdited><Created>2020-04-14T19:51:56.4320018</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Win L.</firstname><surname>Yin</surname><order>1</order></author><author><firstname>Steve</firstname><surname>Bain</surname><orcid>0000-0001-8519-4964</orcid><order>2</order></author><author><firstname>Thinzar</firstname><surname>Min</surname><order>3</order></author></authors><documents><document><filename>53944__17060__e0c0885426c84b11aa6dd255e6142420.pdf</filename><originalFilename>53944VOR.pdf</originalFilename><uploaded>2020-04-14T19:54:57.0338564</uploaded><type>Output</type><contentLength>300660</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>Released under the terms of a Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC).</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc/4.0/</licence></document></documents><OutputDurs/></rfc1807>
spelling 2022-12-02T18:49:20.9521425 v2 53944 2020-04-14 The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes 5399f4c6e6a70f3608a084ddb938511a 0000-0001-8519-4964 Steve Bain Steve Bain true false 27cba511a4800fefddb6885ffffdb8b2 Thinzar Min Thinzar Min true false 2020-04-14 MEDS This review examines the available literature on the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in type 2 diabetes mellitus. Diabetes is an important cause of end-stage renal disease requiring renal replacement therapy, and diabetic kidney disease is an independent risk factor for cardiovascular disease (CVD). GLP-1RAs are proven to be safe in terms of CVD, and some of them have been shown to have a beneficial effect on cardiovascular outcomes. The effect of GLP-1RAs on hard renal endpoints has yet to be established; to date, there have been no published GLP-1RA clinical trials with primary renal endpoints. In this review, we discuss the evidence for a renal protective role of GLP-1RAs, highlighting the secondary renal outcomes from recent cardiovascular outcome trials of this class of glucose-lowering therapies. Journal Article Diabetes Therapy 11 4 835 844 Springer Science and Business Media LLC 1869-6953 1869-6961 Chronic kidney disease; Diabetesrelated nephropathy; Diabetic nephropathy; Dipeptidyl peptidase-4 (DPP-4) inhibitors; Glucagon-like peptide-1 receptor agonists; Type 2 diabetes 1 4 2020 2020-04-01 10.1007/s13300-020-00798-x COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University 2022-12-02T18:49:20.9521425 2020-04-14T19:51:56.4320018 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Win L. Yin 1 Steve Bain 0000-0001-8519-4964 2 Thinzar Min 3 53944__17060__e0c0885426c84b11aa6dd255e6142420.pdf 53944VOR.pdf 2020-04-14T19:54:57.0338564 Output 300660 application/pdf Version of Record true Released under the terms of a Creative Commons Attribution-NonCommercial 4.0 International License (CC-BY-NC). true eng http://creativecommons.org/licenses/by-nc/4.0/
title The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
spellingShingle The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
Steve Bain
Thinzar Min
title_short The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
title_full The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
title_fullStr The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
title_full_unstemmed The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
title_sort The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Renal Outcomes in Type 2 Diabetes
author_id_str_mv 5399f4c6e6a70f3608a084ddb938511a
27cba511a4800fefddb6885ffffdb8b2
author_id_fullname_str_mv 5399f4c6e6a70f3608a084ddb938511a_***_Steve Bain
27cba511a4800fefddb6885ffffdb8b2_***_Thinzar Min
author Steve Bain
Thinzar Min
author2 Win L. Yin
Steve Bain
Thinzar Min
format Journal article
container_title Diabetes Therapy
container_volume 11
container_issue 4
container_start_page 835
publishDate 2020
institution Swansea University
issn 1869-6953
1869-6961
doi_str_mv 10.1007/s13300-020-00798-x
publisher Springer Science and Business Media LLC
college_str Faculty of Medicine, Health and Life Sciences
hierarchytype
hierarchy_top_id facultyofmedicinehealthandlifesciences
hierarchy_top_title Faculty of Medicine, Health and Life Sciences
hierarchy_parent_id facultyofmedicinehealthandlifesciences
hierarchy_parent_title Faculty of Medicine, Health and Life Sciences
department_str Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine
document_store_str 1
active_str 0
description This review examines the available literature on the effect of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on renal outcomes in type 2 diabetes mellitus. Diabetes is an important cause of end-stage renal disease requiring renal replacement therapy, and diabetic kidney disease is an independent risk factor for cardiovascular disease (CVD). GLP-1RAs are proven to be safe in terms of CVD, and some of them have been shown to have a beneficial effect on cardiovascular outcomes. The effect of GLP-1RAs on hard renal endpoints has yet to be established; to date, there have been no published GLP-1RA clinical trials with primary renal endpoints. In this review, we discuss the evidence for a renal protective role of GLP-1RAs, highlighting the secondary renal outcomes from recent cardiovascular outcome trials of this class of glucose-lowering therapies.
published_date 2020-04-01T07:57:22Z
_version_ 1821935028548927488
score 11.048064

Similar Items